LHW090

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Kidney Disease (CKD)Chronic Renal InsufficiencyPatients, Resistant Hypertension

Phase 1

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

CompletedNCT01846468

Novartis PharmaceuticalsChronic Renal Insufficiency

Start: 2013-03-01End: 2014-06-28Updated: 2020-12-17

Phase 2

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

CompletedNCT02515331

Novartis PharmaceuticalsPatients, Resistant Hypertension

Start: 2015-11-04End: 2017-08-17Updated: 2021-01-05

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

CompletedNCT02678000

Novartis PharmaceuticalsChronic Kidney Disease (CKD)

Start: 2017-03-10End: 2018-10-11Updated: 2021-10-06